Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

In this study, androgen did not affect keratinocyte growth in coculture with androgenetic alopecia-derived dermal papilla cells, but did significantly suppress keratinocyte growth when androgen receptor was overexpressed in the papilla cells.

This study found that testosterone and 5α-dihydrotestosterone affect human sebocytes differently depending on the skin region, with spironolactone inhibiting their proliferation and counteracting androgen effects in facial sebocytes.

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

This study identified differences in adverse symptoms among patients with post-finasteride syndrome based on short and long androgen receptor gene polymorphisms.

This study in the Arab population of Gaza described pseudohermaphroditism due to 17β-HSD deficiency, where individuals showed marked masculinization after puberty despite inadequate androgen proportions.

This study found that the less common CAG-rs4045402 and GGN-rs3138869 polymorphisms were more frequent in patients with post-finasteride syndrome and androgenetic alopecia, suggesting a genetic predisposition to AGA development.

This study found that chronic administration of testosterone in mice induced an elevated EPO secretion response, possibly mediated through DHT, without affecting baseline EPO levels.

This study found that adding the Liangxue Zhituo prescription to a 5% minoxidil treatment resulted in a significantly higher improvement rate for patients with androgenic alopecia compared to minoxidil alone, with no significant adverse reactions reported.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This study observed that the cream-mask and gel-mask with Serenoa repens and Sophora japonica applied to a rat model of androgenic alopecia stimulated hair follicle growth similarly to a reference minoxidil treatment.

This study found that variations in (CAG)n and (GGN)n polymorphisms in the androgen receptor gene appear to influence symptom severity in men with post-finasteride syndrome.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

In this study, researchers found that steroidal 17β-carboxamides 1-4 significantly inhibited 5α-reductase enzyme activity and reduced prostate weight more effectively than finasteride in a hamster model, without toxic side effects, suggesting potential for treating benign prostatic hyperplasia.

Masculinization in affected individuals occurs gradually after puberty due to hormone changes.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

This review discusses the complex dermatological effects of oral contraceptives, including both hormonal benefits and potential toxicities, but reports no new clinical results.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

This review discusses the physiological roles of ovarian androgens in follicle development and atresia, emphasizing their contributions to polycystic ovary syndrome and normal follicle maturation but provides no new clinical results.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

Testosterone therapy can help improve mood, sexual function, and bone health in women with low androgen levels, but more research is needed to establish safe and effective guidelines.

This review discusses the benefits and cardiovascular risks of androgen deprivation therapy for prostate cancer patients, noting that optimizing cardiovascular risk factors is important when using ADT.

In this study, vitamin D supplementation showed no significant effect on androgen levels or clinical hyperandrogenism in PCOS women, but when combined with metformin, it improved testosterone levels.

This review discusses the presence of undeclared substances, including androgenic steroids, in sports supplements and emphasizes potential health risks, without providing new results; it advises caution and consultation on supplement use.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.